According to the report published by Allied Market Research, the global rheumatoid arthritis drug market was estimated at $57.92 billion in 2019 and is expected to hit $62.93 billion by 2027. Rise in the prevalence of rheumatoid arthritis, surge in geriatric population, and transition from symptom management to slowing the progression of the disease are the major factors that drive the growth of the global rheumatoid arthritis drugs market. Developments in the field of biosimilars and novel biologics are expected to pave the way for new opportunities in the industry.